In late 2020, after circulating for almost a year in the human population, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its …

A diverse array of successful, first-generation SARS-CoV-2 vaccines have played a huge
role in efforts to bring the COVID-19 pandemic under control, even though inequitable …

The Omicron, or Pango lineage B. 1.1. 529, variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and …

The severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is spreading rapidly, even in vaccinated individuals, raising concerns about immune …

INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA
vaccines are highly effective at preventing infection and especially severe disease …

More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over …

Individuals with potential exposure to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) do not necessarily develop PCR or antibody positivity, suggesting that some …

The germinal centre (GC) response is critical for the generation of affinity-matured plasma
cells and memory B cells capable of mediating long-term protective immunity …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell
responses that continue to evolve for at least a year. During that time, memory B cells …